HQL — Tekla Life Sciences Investors stock price, charts and financials
QT74Tekla Life Sciences InvestorsTekla Life Sciences Investors (NYSE: HQL) is a Financial Services company in the Asset Management industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 2.83 | EPS (ttm) | 6.75 | Insider Own | 12.04% | Shs Outstand | 30.41M | Perf Week | -0.78% |
| Market Cap | 580.79M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.01% | Shs Float | 27.44M | Perf Month | -4.40% |
| Enterprise Value | 580.79M | PEG | 0.00 | EPS next Q | - | Inst Own | - | Short Float | 0.23% | Perf Quarter | 9.14% |
| Income | 198.17M | P/S | 9.73 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.54 | Perf Half Y | 11.96% |
| Sales | 59.70M | P/B | 1.04 | EPS next Y | - | ROA | 35.18% | Short Interest | 62.73K | Perf YTD | 13.83% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 36.89% | 52W High | 21.51 -10.41% | Perf Year | 44.26% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - -10.52% | ROIC | 35.24% | 52W Low | 13.13 46.81% | Perf 3Y | 42.22% |
| Dividend Est. | 2.24 (11.62%) | EV/EBITDA | 2.93 | Sales past 3/5Y | 39.03% 17.14% | Gross Margin | 90.69% | Volatility | 2.21% 2.44% | Perf 5Y | -8.57% |
| Dividend TTM | 2.04 (10.59%) | EV/Sales | 9.73 | EPS Y/Y TTM | 122.04% | Oper. Margin | - | ATR (14) | 0.47 | Perf 10Y | 2.85% |
| Dividend Ex-Date | May 21, 2026 | Quick Ratio | 2.58 | Sales Y/Y TTM | -31.03% | Profit Margin | - | RSI (14) | 45.63 | Recom | - |
| Dividend Gr. 3/5Y | 10.20% 3.13% | Current Ratio | 2.58 | EPS Q/Q | -226.82% | SMA20 | -3.61% | Beta | 0.70 | Target Price | - |
| Payout | 25.13% | Debt/Eq | 0.00 | Sales Q/Q | 2300.00% | SMA50 | 2.40% | Rel Volume | 1.12 | Prev Close | 19.10 |
| Employees | - | LT Debt/Eq | 0.00 | Earnings | - | SMA200 | 9.64% | Avg Volume | 132.52K | Price | 19.27 |
| IPO Date | May 01, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | - | Net Debt/EBITDA | 0.00 | Volume | 148,740 | Change | 0.89% |
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 60 | 86 | 87 | 39 | 32 | 45 | 39 | 2 | 2 | |
| Cost of Goods Sold Incl. D&A | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 0 | 0 | |
| Gross Profit | 54 | 86 | 87 | 18 | 26 | 39 | 34 | 2 | 2 | |
| Selling, General and Administrative Excl. Other | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | -148 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | 198 | 86 | 85 | -5 | -105 | 65 | 123 | -3 | -4 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 0 | 0 | 28 | 0 | 0 | 0 | -68 | 32 | |
| Net Income Before Taxes | 198 | 86 | 85 | 22 | -105 | 65 | 123 | -70 | 29 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | 198 | 86 | 85 | 22 | -105 | 65 | 123 | -70 | 29 | |
| Net Income From Continuing Operations | 198 | 86 | 85 | 22 | -105 | 65 | 123 | -70 | 29 | |
| Net Income | 198 | 86 | 85 | 22 | -105 | 65 | 123 | -70 | 29 | |
| EPS (Recurring) | 6.75 | 2.96 | 3.04 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | |
| EPS (Basic, Before Extraordinaries) | 6.75 | 2.96 | 3.04 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | |
| EPS (Diluted) | 6.75 | 2.96 | 3.04 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | |
| EBITDA | 198 | 86 | 87 | 50 | -102 | 69 | 123 | 0 | 0 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 2.85 | 5.24 | 4.96 | 15.78 | — | 7.82 | 3.41 | — | 15.95 | |
| Price To Sales Ratio | 9.64 | 5.23 | 4.85 | 8.95 | 11.10 | 11.09 | 10.82 | 173.65 | 224.62 | |
| Gross Margin | 90.00 | 100.00 | 100.00 | 46.15 | 81.25 | 86.67 | 87.18 | 100.00 | 100.00 | |
| Operating Margin | 330.00 | 100.00 | 97.70 | -12.82 | -328.13 | 144.44 | 315.38 | -150.00 | -200.00 | |
| Net Margin | 330.00 | 100.00 | 97.70 | 56.41 | -328.13 | 144.44 | 315.38 | -3,500.00 | 1,450.00 | |
| Shares Outstanding | 30 | 29 | 28 | 28 | 26 | 24 | 24 | 23 | 22 | |
| Market Capitalization | 578 | 450 | 422 | 349 | 355 | 499 | 422 | 347 | 449 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mahai Chris LaVictoire | Director | Jul 16 '26 | Buy | 19.92 | 527 | 10,498 | 527 | Jul 20 |
| Pittard Christian | Director | Dec 16 '25 | Buy | 16.88 | 7,923 | 133,755 | 7,923 | Dec 18 |
| Saba Capital Management, L.P. | 10% Owner | Sep 22 '25 | Sale | 14.14 | 41,623 | 588,549 | 2,837,633 | Sep 23 |
| Saba Capital Management, L.P. | 10% Owner | Sep 19 '25 | Sale | 14.10 | 6,989 | 98,545 | 2,879,256 | Sep 23 |
| Saba Capital Management, L.P. | 10% Owner | Sep 18 '25 | Sale | 14.07 | 40,208 | 565,727 | 2,886,245 | Sep 19 |
| Saba Capital Management, L.P. | 10% Owner | Sep 17 '25 | Sale | 13.99 | 24,328 | 340,349 | 2,926,453 | Sep 19 |
| Saba Capital Management, L.P. | 10% Owner | Sep 16 '25 | Sale | 13.99 | 2,026 | 28,344 | 2,950,781 | Sep 17 |
| Saba Capital Management, L.P. | 10% Owner | Sep 15 '25 | Sale | 14.13 | 700 | 9,891 | 2,952,807 | Sep 17 |
| Saba Capital Management, L.P. | 10% Owner | Sep 11 '25 | Sale | 14.28 | 15,116 | 215,856 | 2,953,507 | Sep 15 |
| Saba Capital Management, L.P. | 10% Owner | Sep 02 '25 | Sale | 14.04 | 14,083 | 197,725 | 2,968,623 | Sep 04 |
| Saba Capital Management, L.P. | 10% Owner | Aug 29 '25 | Sale | 13.89 | 23,723 | 329,512 | 2,982,706 | Sep 02 |
| Saba Capital Management, L.P. | 10% Owner | Aug 26 '25 | Sale | 13.83 | 400 | 5,532 | 3,006,429 | Aug 27 |
| Saba Capital Management, L.P. | 10% Owner | Aug 21 '25 | Sale | 14.07 | 10,710 | 150,690 | 3,006,829 | Aug 25 |
| Saba Capital Management, L.P. | 10% Owner | May 20 '25 | Sale | 12.71 | 11,419 | 145,135 | 3,017,539 | May 22 |
| Saba Capital Management, L.P. | 10% Owner | May 15 '25 | Sale | 12.08 | 23,729 | 286,646 | 3,028,958 | May 19 |